Dai Y - Search Results

1

Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.

Zang M, Li Z, Liu L, Li F, Li X, Dai Y, Li W, Kuckelkorn U, Doeppner TR, Hermann DM, Zhou W, Qiu L, Jin F. Zang M, et al. Among authors: dai y. Cancer Lett. 2015 Oct 1;366(2):173-81. doi: 10.1016/j.canlet.2015.06.011. Epub 2015 Jun 23. Cancer Lett. 2015. PMID: 26116344

2

Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.

Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R, Dent P, Grant S. Dai Y, et al. Cancer Res. 2001 Jul 1;61(13):5106-15. Cancer Res. 2001. PMID: 11431348

3

The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.

Pei XY, Dai Y, Grant S. Pei XY, et al. Among authors: dai y. Leukemia. 2003 Oct;17(10):2036-45. doi: 10.1038/sj.leu.2403109. Leukemia. 2003. PMID: 14513055

4

Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.

Dai Y, Rahmani M, Grant S. Dai Y, et al. Oncogene. 2003 Oct 16;22(46):7108-22. doi: 10.1038/sj.onc.1206863. Oncogene. 2003. PMID: 14562039

5

The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, Grant S. Maggio SC, et al. Among authors: dai y. Cancer Res. 2004 Apr 1;64(7):2590-600. doi: 10.1158/0008-5472.can-03-2631. Cancer Res. 2004. PMID: 15059916

6

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.

Pei XY, Dai Y, Grant S. Pei XY, et al. Among authors: dai y. Clin Cancer Res. 2004 Jun 1;10(11):3839-52. doi: 10.1158/1078-0432.CCR-03-0561. Clin Cancer Res. 2004. PMID: 15173093

7

The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.

Pei XY, Dai Y, Grant S. Pei XY, et al. Among authors: dai y. Mol Cancer Ther. 2004 Dec;3(12):1513-24. Mol Cancer Ther. 2004. PMID: 15634644

8

The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.

Pei XY, Dai Y, Rahmani M, Li W, Dent P, Grant S. Pei XY, et al. Among authors: dai y. Clin Cancer Res. 2005 Jun 15;11(12):4589-600. doi: 10.1158/1078-0432.CCR-04-2346. Clin Cancer Res. 2005. PMID: 15958645

9

Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry.

Dai Y, Hamm TE, Dent P, Grant S. Dai Y, et al. Cell Cycle. 2006 Feb;5(4):437-46. doi: 10.4161/cc.5.4.2441. Epub 2006 Feb 15. Cell Cycle. 2006. PMID: 16479154

10

Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.

Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S. Dai Y, et al. Clin Cancer Res. 2008 Jan 15;14(2):549-58. doi: 10.1158/1078-0432.CCR-07-1934. Clin Cancer Res. 2008. PMID: 18223231

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12,692 results

Search Page

Filters